A fourth vaccine dose to Corona is expected to improve the protection of cancer patients - it is expected to cause an increase in antibodies in their bodies and without side effects, says Dr. Hagai Ligomsky, a senior oncologist at Ichilov, who studied the effect of the third vaccine on active cancer patients. Metastatic and during chemotherapy.
Although the study examined only the consequences of the third vaccine dose, based on the results, Ichilov estimates that a fourth vaccine dose will benefit this group of patients.
In a study conducted at the Ichilov Oncology Division and the results of which are published in the prestigious Lancet Oncology journal, it was found that after more than six months from the second vaccine dose to Corona, the antibody levels are declining.
Among the cancer patient population, the decrease was significant compared to healthy subjects: 20% of cancer patients were found to have no antibodies, compared with 1% in the healthy population.
The study found that after the booster dose only three cancer patients (4%) were still without antibodies and none of the control group.
The main side effects reported were injection site pain, swelling and fatigue.
Dr. Ligomsky, Photo: Miri Gatnio, Ichilov Spokeswoman
"It appears that giving a fourth vaccine dose can contribute to protection for this population," the study's authors note.
Dr. Hagai Ligomsky: "We would like to continue the research before and after the fourth vaccine dose.
The findings are encouraging, because it is known that patients are not only more vulnerable but also the vaccine is less effective, and there is a concern that chemotherapy treatments impair the effectiveness of the vaccine. "
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us
